| |
| | 5ht7 antagonists and inverse agonists patent invention (Site not responding. Last check: 2007-11-03) |
 | | [0405] The title compound was prepared in an analogous fashion to Example 7, Step 3, utilizing the title compound from Example 9, Step 1 (51 mg, 0.14 mmol) in 0.75 ml toluene, 1-methyl piperazine (91 ul, 0.81 mmol), palladium(II)acetate (6.4 mg, 0.028 mmol), 2,2'-bisdiphenylphosphanyl-[1,- 1']binaphthalenyl (17.4 mg, 0.028 mmol) and sodium-tert-butoxide (108 mg, 1.1 mmol). |
 | | [0416] The title compound was prepared in an analogous fashion to Example 7, Step 3, utilizing the title compound from Example 10, Step 1 (112 mg, 0.31 mmol) in 2.0 ml toluene, 1-methyl piperazine (207 ul, 1.86 mmol), palladium(II)acetate (142 mg, 0.62 mmol), 2,2'-bisdiphenylphosphanyl-[1,1- ']binaphthalenyl (386 mg, 0.62 mmol) and sodium-tert-butoxide (238 mg, 2.48 mmol). |
 | | [0427] The title compound was prepared in an analogous fashion to Example 7, Step 3, utilizing the title compound from Example 11, Step 1 (234 mg, 0.62 mmol) in 3.0 ml toluene, 1-methyl piperazine (416 ul, 13.7 mmol), palladium(II)acetate (28.5 mg, 0.12 mmol), 2,2'-bisdiphenylphosphanyl-[1,- 1']binaphthalenyl (77 mg, 0.12 mmol) and sodium-tert-butoxide (358 mg, 3.7 mmol). |
| www.freshpatents.com /5ht7-antagonists-and-inverse-agonists-dt20041118ptan20040229874.php?type=description (12930 words) |
|